Brought to you by 
Fresenius to acquire APP Pharmaceuticals for $3.7bn
09 Jul 2008
Executive Summary
Germany's Fresenius SE (hospital, home care, and dialysis products) will pay $23 per share in cash (a 40% premium) to acquire all of the outstanding stock of US-based injectables manufacturer APP Pharmaceuticals. The deal is valued at about $3.7bn, plus the assumption of $940mm in debt, and the potential of an additional $970mm in sales-based earn-outs (what the companies refer to as "contingent value right").
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Medical Devices
- Infusion Therapy Equipment and Supplies
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fresenius to acquire APP Pharmaceuticals for $3.7bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice